Veracyte is a diagnostics company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs.
We specifically target diseases that often require invasive procedures for an accurate diagnosis – diseases where many patients undergo costly interventions that ultimately prove unnecessary.
We improve the accuracy of diagnosis at an earlier stage of patient care by deriving clinically actionable genomic information from cytology samples collected in an outpatient setting.
Our tests are designed to answer a relevant clinical question and, when used at the optimal point in the diagnostic pathway, provide physicians with information that can significantly alter their decision‑making, enabling patients to potentially avoid unnecessary invasive and costly procedures.